𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis

✍ Scribed by Pfeiffer, P; Nexø, E; Bentzen, SM; Clausen, PP; Andersen, K; Rose, C

Book ID
109838544
Publisher
Nature Publishing Group
Year
1998
Tongue
English
Weight
653 KB
Volume
78
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor immunoh
Epidermal growth factor receptor immunohistochemistry : Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
✍ Fred R. Hirsch; Rafal Dziadziuszko; Nick Thatcher; Helen Mann; Claire Watkins; D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The ISEL (Iressa Survival Evaluation in Lung Cancer) clinical trial evaluated the efficacy of gefitinib versus placebo in pretreated nonsmall‐cell lung cancer patients. Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR)

Detection of epidermal growth factor rec
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_